Sort   by:  
 Page size 
MetabolomicsAlterations in the gut microbiota and metabolic profiles coincide with intestinal damage in mice with a bloodborne Candida albicans infection
Candida albicans is an opportunistic fungus that can threaten life especially in patients with candidemia. The morbidity and mortality of candidemia originating from a central venous catheter (CVC) and illicit intravenous drug use (IVDU) are increasing. However, the mechanism underlying the bloodbor...
2021-04-13 | MTBLS1918 | MetaboLights
UnknownOptical control of membrane tethering and interorganellar communication at nanoscales.
Not available
S-EPMC5606013 | biostudies-literature
ProteomicsSARS-CoV-2 spike protein glycosylation enriched by HILIC and Ti-IMAC
In this work, we performed a fully descriptive analysis N- and O- linked glycosylation of SARS-COV-2 S glycoprotein. We investigated that dual-functionalized Ti-IMAC material enable the simultaneous enrichment and separation of neutral and sialyl glycopeptides of a recombinant SARS-CoV-2 S glycoprot...
ORGANISM(S): Homo sapiens (Human) 
2022-01-11 | PXD026450 | Pride
Sars-cov-2 Spike protein 
MetabolomicsCharacterization of white tea metabolome: comparison against green and black tea by a nontargeted metabolomics approach
White tea is considered the least processed form of tea and is reported to have a series of potent bioactivities, such as antioxidant, anti-inflammatory, anti-mutagenic, and anti-cancer activities. However, the chemical composition of white tea and the dynamic changes of the metabolites during the m...
2017-03-23 | MTBLS403 | MetaboLights
ProteomicsProtective mechanisms of heparin against AGEs-induced endothelial injury
Advanced glycation end products (AGEs) in diabetes can cause endothelial damage. Heparin, widely known as a recognized anticoagulant, is also a multifunctional therapeutic drug. This study investigated whether heparin could ameliorate AGEs-induced endothelial injury. Remarkably, heparin effectively ...
ORGANISM(S): Homo Sapiens 
2025-01-19 | PXD056219 |
UnknownSelection criteria for large core trials: rationale for the ANGEL-ASPECT study design.
Not available
S-EPMC8785010 | biostudies-literature
Sort   by:  
 Page size